Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device; and cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. The company also provides FiberCel, ViBone, and OsterGro V that are designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. In addition, it offers contract manufacturing services for various products to corporate customers. The company sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. Aziyo Biologics, Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
IPO Year: 2020
Exchange: NASDAQ
Website: aziyo.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/4/2022 | $15.00 → $13.00 | Outperform | Cowen & Co. |
Cowen & Co. reiterated coverage of Aziyo Biologics with a rating of Outperform and set a new price target of $13.00 from $15.00 previously
4 - ELUTIA INC. (0001708527) (Issuer)
4 - ELUTIA INC. (0001708527) (Issuer)
SILVER SPRING, Md., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a regenerative medicine company with a portfolio of commercial therapies, today announced the appointment of David Colpman to its Board of Directors and audit committee, effective October 20, 2022. His appointment brings the company's Board of Directors to six members. "David's impressive commercial expertise was vital in guiding some of the world's largest and most-well respected biopharmaceutical companies in achieving their growth milestones," said Dr. Randy Mills, Chief Executive Officer of Aziyo Biologics. "We specifically sought a Board member, like David, whose deep industry insights and busi
SILVER SPRING, Md., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company announced today that Michelle LeRoux Williams, Ph.D. has been appointed Chief Scientific Officer. "Aziyo strives to have the best products in the markets in which we choose to compete, and Dr. Williams has the expertise and leadership to help us deliver just that," said Dr. Randy Mills, Chief Executive Officer. "Michelle has been a thought leader in regenerative medicine for two decades. She has a track record of consistently developing commercially successful products, including Osteocel®, the world's first stem cell product with cumulative sales of
SILVER SPRING, Md., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the appointment of Peter G. Edwards as General Counsel. "We are delighted to welcome such a strong and experienced leader as Peter to our executive team," said Ron Lloyd, President and Chief Executive Officer of Aziyo. "We expect his deep experience serving as general counsel to high growth companies, particularly in the healthcare sector, will prove to be invaluable as we head into our next phase of growth. We have
Negotiating multiple LOIs to divest Orthopedic business CanGaroo® RM 510(k) resubmission to the FDA remains on track SimpliDerm® quarterly net sales up 32% year-over-year Successful transfer of Cardiovascular product distribution to LeMaitre Vascular SILVER SPRING, Md., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today provided a business update and reported financial results for the second quarter ended June 30, 2023. "Our strategy to transform Aziyo into a high growth drug-eluting biomatrix product company
SILVER SPRING, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its second quarter 2023 financial results after market close on Monday, August 14, 2023. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click here U.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID:
- All Four Business Segments Achieved Growth Led by Strong SimpliDerm and CanGaroo Sales - SILVER SPRING, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today provided a business update and reported financial results for the first quarter ended March 31, 2023. Business Highlights: Net sales rose 14% compared to the prior-year period, to a record $13.1 million for first quarter 2023.Gross margin increased 11 percentage points year-over-year to 49%.Signed a partnership with LeMaitre Vascular to distribute Aziyo'
SILVER SPRING, Md., May 03, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its first quarter 2023 financial results after market close on Wednesday, May 10, 2023. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click here U.S. Investors: 888-272-8703International Investors: 713-481-1320Conference ID: 1
SILVER SPRING, Md., March 20, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, provides an update on its submission to the U.S. Food and Drug Administration (FDA) for the CanGaroo® RM Antibacterial Envelope, the Company's next-generation biomaterial envelope. The device is intended to securely hold a cardiac implantable electronic device or neurostimulator, creating a stable environment when implanted in the body. The CanGaroo RM Antibacterial Envelope contains the antibiotics rifampin and minocycline, which have been shown in preclinica
SILVER SPRING, Md., March 15, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its fourth quarter and full year 2022 financial results after market close on Wednesday, March 22, 2023. Members of the Company's management team will host a conference call and webcast with accompanying slides starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click here U.S. Investors: 877-407-8029Inter
Positive meeting with FDA provides clarity for CanGaroo® RM clearance SILVER SPRING, Md., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today provided a business update and reported financial results for the third quarter ended September 30, 2022. Recent Highlights Positive meeting with FDA provided clarity on path for first quarter 2023 clearance of the CanGaroo® RM Antibacterial EnvelopeStrong growth with net sales of $12.4 million, an 8% increase over third quarter of 2021Device compatibility business units (Simpl
Conference Call and Live Audio Webcast Scheduled for Thursday, November 10, 2022, at 10:00 a.m. ET Corporate Highlights Successful leadership transition with Jody Staggs named President and Interim Chief Executive Officer and Yvette Heinrichson named Chief Financial OfficerClosed three new transactions during the quarter, totaling $57.5 million of committed capitalSubsidiary Enteris achieved $5.0 million milestone with Cara Therapeutics; SWK will retain $2.5 millionRepurchased 34,463 shares of common stock during the quarter for a total cost of $0.6 millionThird quarter 2022 GAAP net income was $6.6 million or $0.51 per diluted shareFinance Receivables Segment Update Third quarter 2022 GAAP
SILVER SPRING, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a regenerative medicine company with a portfolio of commercial therapies, today announced that it will release third quarter 2022 financial results after market close on Monday, November 14, 2022. Members of the Company's management team will host a conference call and webcast with accompanying slides starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 866-682-6100International Investors: 862-298-0702Conference ID: 13734285 Please log in approximately 10 minutes pr
Third Quarter 2022 Financial Results to be Announced in Early November DALLAS, Oct. 18, 2022 /PRNewswire/ -- SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an update on the progress and achievements of its borrower partners, including recent transactions and activities. "The second half of 2022 has been an active time for SWK. We have capitalized on our strong underlying business fundamentals to close several transactions, including two $25.0 million financings with Aziyo Biologics and MedMinder," stated Jody Staggs, President and Interim CEO of SWK.
SC 13G - ELUTIA INC. (0001708527) (Subject)
SC 13G/A - ELUTIA INC. (0001708527) (Subject)
SC 13D/A - ELUTIA INC. (0001708527) (Subject)
SC 13G - ELUTIA INC. (0001708527) (Subject)
SC 13D/A - ELUTIA INC. (0001708527) (Subject)
SC 13G/A - AZIYO BIOLOGICS, INC. (0001708527) (Subject)
SC 13G/A - AZIYO BIOLOGICS, INC. (0001708527) (Subject)
SC 13G/A - AZIYO BIOLOGICS, INC. (0001708527) (Subject)
SC 13G/A - AZIYO BIOLOGICS, INC. (0001708527) (Subject)
SC 13G/A - AZIYO BIOLOGICS, INC. (0001708527) (Subject)
4 - ELUTIA INC. (0001708527) (Issuer)
4 - ELUTIA INC. (0001708527) (Issuer)
4 - ELUTIA INC. (0001708527) (Issuer)
4 - ELUTIA INC. (0001708527) (Issuer)
4 - ELUTIA INC. (0001708527) (Issuer)
4 - ELUTIA INC. (0001708527) (Issuer)
4 - ELUTIA INC. (0001708527) (Issuer)
3 - ELUTIA INC. (0001708527) (Issuer)
4 - ELUTIA INC. (0001708527) (Issuer)
4 - AZIYO BIOLOGICS, INC. (0001708527) (Issuer)
424B3 - ELUTIA INC. (0001708527) (Filer)
8-K - ELUTIA INC. (0001708527) (Filer)
S-8 - ELUTIA INC. (0001708527) (Filer)
8-K - ELUTIA INC. (0001708527) (Filer)
8-K - ELUTIA INC. (0001708527) (Filer)
8-K - ELUTIA INC. (0001708527) (Filer)
8-K - ELUTIA INC. (0001708527) (Filer)
424B3 - ELUTIA INC. (0001708527) (Filer)
EFFECT - ELUTIA INC. (0001708527) (Filer)
S-3 - ELUTIA INC. (0001708527) (Filer)
SILVER SPRING, Md., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation will take place in New York on Wednesday, September 13, 2023, at 2:30 pm ET. A live webcast of the presentation can be accessed by visiting the Company's Events & Presentations webpage or by clicking here. A replay will be available on the Company's website following the event. Institutional investors interested in meeting with management during the conference may reach out
– Company to begin trading under new ticker symbol "ELUT" – SILVER SPRING, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo") today announced a change of the Company's name to Elutia Inc. The rebranding reflects the strategic focus to develop and commercialize proprietary drug-eluting biomatrix technology aimed at improving surgical outcomes. The name change becomes effective today, September 6, 2023. The Company's stock will begin trading on Nasdaq under the new ticker symbol "ELUT" on September 7, 2023. "We are excited to introduce Elutia, where we exist to humanize medicine by pioneering drug-eluting biomatrix or DEB technology," said Dr. Randy Mills
Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket SILVER SPRING, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced the publication of a case report highlighting results that demonstrate the potential benefits of using a biological device envelope during reoperative procedures for CIEDs. The report, titled "Rehabilitation of an Existing Device Implant Pocket Using a Biolog
Negotiating multiple LOIs to divest Orthopedic business CanGaroo® RM 510(k) resubmission to the FDA remains on track SimpliDerm® quarterly net sales up 32% year-over-year Successful transfer of Cardiovascular product distribution to LeMaitre Vascular SILVER SPRING, Md., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today provided a business update and reported financial results for the second quarter ended June 30, 2023. "Our strategy to transform Aziyo into a high growth drug-eluting biomatrix product company
SILVER SPRING, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its second quarter 2023 financial results after market close on Monday, August 14, 2023. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click here U.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID:
DALLAS, July 17, 2023 /PRNewswire/ -- SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower partners. "During the second quarter of 2023 SWK advanced our 2023 objectives including securing a new four-year credit facility with First Horizon Bank with $45 million committed at close," stated Jody Staggs, President and CEO of SWK. "This credit facility enables us
SILVER SPRING, Md., July 13, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced a voluntary recall of its viable bone matrix products, which are bone repair products made from human tissue that are used primarily in orthopedic and spinal procedures. Notice of the voluntary recall was issued to centers after the Company learned of post-surgical Mycobacterium tuberculosis (MTB) infections in two patients treated with viable bone matrix product from a single donor lot. Prior to release, samples from this specific lot had test
Study Presented at Heart Rhythm Society Supports Wound-Healing Benefits in Patients Receiving Cardiac Implantable Electronic Devices SILVER SPRING, Md., May 19, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that positive data from the HEAL Study will be presented at Heart Rhythm Society (HRS 2023) on May 21, 2023, at 12:30 PM CT at the Morial Convention Center in New Orleans, LA. HEAL is a national multi-center study evaluating patients who previously underwent implantation of a cardiac implantable electron
- All Four Business Segments Achieved Growth Led by Strong SimpliDerm and CanGaroo Sales - SILVER SPRING, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today provided a business update and reported financial results for the first quarter ended March 31, 2023. Business Highlights: Net sales rose 14% compared to the prior-year period, to a record $13.1 million for first quarter 2023.Gross margin increased 11 percentage points year-over-year to 49%.Signed a partnership with LeMaitre Vascular to distribute Aziyo'
SILVER SPRING, Md., May 03, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its first quarter 2023 financial results after market close on Wednesday, May 10, 2023. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click here U.S. Investors: 888-272-8703International Investors: 713-481-1320Conference ID: 1
Cantor Fitzgerald analyst Brandon Folkes reiterates Aziyo Biologics (NASDAQ:AZYO) with a Overweight and maintains $8 price target.
– Company to begin trading under new ticker symbol "ELUT" – SILVER SPRING, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo") today announced a change of the Company's name to Elutia Inc. The rebranding reflects the strategic focus to develop and commercialize proprietary drug-eluting biomatrix technology aimed at improving surgical outcomes. The name change becomes effective today, September 6, 2023. The Company's stock will begin trading on Nasdaq under the new ticker symbol "ELUT" on September 7, 2023. "We are excited to introduce Elutia, where we exist to humanize medicine by pioneering drug-eluting biomatrix or DEB technology," said Dr. Randy Mills
Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket
Gainers Timber Pharmaceuticals (AMEX:TMBR) stock moved upwards by 97.9% to $2.81 during Monday's regular session. Timber Pharmaceuticals's stock is trading at a volume of 17.3 million shares as of 13:31 EST. This is 3771.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $8.5 million. China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 89.15% to $0.28. As of 13:31 EST, this security is trading at a volume of 116.9 million shares, making up 26232.6% of its average full-day volume over the last 100 days. The company's market cap stands at $3.9 million. Novo Integrated Sciences (NASDAQ:NVOS) stock increased by 45.48% to $0.19.
Cantor Fitzgerald analyst Brandon Folkes reiterates Aziyo Biologics (NASDAQ:AZYO) with a Overweight and maintains $8 price target.
Aziyo Biologics (NASDAQ:AZYO) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.29) by 124.14 percent. This is a 5.8 percent increase over losses of $(0.69) per share from the same period last year. The company reported quarterly sales of $10.30 million which missed the analyst consensus estimate of $12.50 million by 17.63 percent. This is a 18.53 percent decrease over sales of $12.64 million the same period last year.
Aziyo Biologics Inc (NASDAQ:AZYO) announced that data from the HEAL Study will be presented at the Heart Rhythm Society this Sunday. HEAL is a national multi-center study evaluating patients who previously underwent implantation of a cardiac implantable electronic device (CIED) with either an Aziyo CanGaroo Envelope, Medtronic Plc's (NYSE:MDT) Tyrx non-biologic envelope, or no envelope, and are returning for a revision procedure at least four months after initial placement. The CanGaroo Envelope is made of an acellular biologic matrix designed to promote a natural healing response, resulting in a healthy, vascularized tissue capsule. The poster to be presented at HRS 2023 comprises dat
Study Presented at Heart Rhythm Society Supports Wound-Healing Benefits in Patients Receiving Cardiac Implantable Electronic Devices SILVER SPRING, Md., May 19, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that positive data from the HEAL Study will be presented at Heart Rhythm Society (HRS 2023) on May 21, 2023, at 12:30 PM CT at the Morial Convention Center in New Orleans, LA. HEAL is a national multi-center study evaluating patients who previously underwent implantation of a cardiac implantable electron